According to this new report, the global cervical cancer market is estimated to be valued at US$ 10.3 billion in the year 2028, growing at a CAGR of 5.2% in the period 2020 to 202. Growth of the market is driven by the prevalence of cervical cancer cases, rising incidences of HIV in women, increasing healthcare expenditure, favorable government initiatives and the advent of targeted therapies.
Cervical cancer is one of the most commonly diagnosed cancers among women. It is also the leading cause of cancer death. It is caused due to uncontrolled growth of tissues in the cervix which eventually leads to massive cancerous growth. Cervical cancers are broadly classified into three categories - Squamous Cell Carcinoma, Adenocarcinoma and Adenosquamous Carcinomas.
T-cell immunotherapy provides immense growth opportunities for cervical cancer treatment. It is one of the few biologics that has been approved for cervical cancer treatment and has a broader therapeutic potential for the disease. There are several T-cell therapy drugs under the clinical trial pipeline of various companies that are expected to gain approval in the near-term.
Segments Covered
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented global cervical cancer market reports on the basis of geography, products, types and end-users.
Type Outlook
Product Outlook
Regional Outlook
Country Outlook
Vendors Outlook
Target Audience
